First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2015.1115641

First oncolytic virus approved for melanoma immunotherapy

Oncoimmunology. 2015 Dec 8;5(1):e1115641. doi: 10.1080/2162402X.2015.1115641. eCollection 2016.

Authors

Jonathan Pol¹, Guido Kroemer², Lorenzo Galluzzi³

Affiliations

¹ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France.
² INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden; Share senior co-authorship.
³ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Share senior co-authorship.

Abstract

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX^GM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

Keywords: Granulocyte macrophage colony-stimulating factor; Imlygic®; OPTiM; OncoVEXGM-CSF; T-vec; talimogene laherparepvec.

Publication types

Research Support, Non-U.S. Gov't